Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
The therapeutic efficacy of dendritic cell (DC)-based immunotherapy may be potentiated in combination with other anticancer therapies that enhance DC function by modulating immune responses and the tumor microenvironment. In this study, we investigated the efficacy of DC vaccination in combination w...
Main Authors: | Manh-Cuong Vo, Sung-Hoon Jung, Tan-Huy Chu, Hyun-Ju Lee, Thangaraj Jaya Lakshmi, Hye-Seong Park, Hyeoung-Joon Kim, Joon Haeng Rhee, Je-Jung Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01370/full |
Similar Items
-
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
by: Manh-Cuong Vo, et al.
Published: (2018-08-01) -
Cellular immunotherapy in multiple myeloma
by: Manh-Cuong Vo, et al.
Published: (2019-09-01) -
Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
by: Ga-Young Song, et al.
Published: (2019-01-01) -
Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
by: Ga-Young Song, et al.
Published: (2020-08-01) -
Simultaneous myelodisplasia and multiple myeloma successfully treated with lenalidomide
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)